Jun 05, 2023
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
Additional Formats
May 19, 2023
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
Additional Formats
May 11, 2023
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
Additional Formats
May 02, 2023
Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
Additional Formats
Apr 17, 2023
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
Additional Formats
Mar 30, 2023
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
Additional Formats
Feb 01, 2023
Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day
Additional Formats
Jan 12, 2023
Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
Additional Formats